| Outcome Measures: |
Primary: The percentage of patients with at least a 0.7% change in the absolute value of glycated hemoglobin, The primary endpoint of the trial is a composite endpoint reflected by the percentage of patients with at least a 0.7% change in the absolute value of glycated hemoglobin and without hypoglycemia after 5 weeks of treatment., Baseline and week5 | Secondary: After five weeks of treatment, the differences in the percentages of patients with at least 3% weight loss, After five weeks of treatment, the differences in the percentages of patients with at least 3% weight loss (compared to their baseline weights) in the two treatment groups, Baseline and week5|The percentage of subjects whose blood glucose levels are within the normal range, The percentage of subjects whose blood glucose levels are within the normal range after five weeks of treatment, Baseline and week5|The time required for patients' blood glucose levels to reach the normal range, The time (days) required for patients' blood glucose levels to reach the normal range during the five-week treatment, Baseline and week5|Body weights of the two patient groups, Body weights of the two patient groups after the five-week treatment, Baseline and week5|Waist circumferences of the two patient groups, Waist circumferences of the two patient groups after the five-week treatment, Baseline and week5|BMIs of the two patient groups, BMIs of the two patient groups after the five-week treatment, Baseline and week5|Waist-to-hip ratios (WHRs) of the two patient groups, Waist-to-hip ratios (WHRs) of the two patient groups after the five-week treatment, Baseline and week5|Changes in the function of islet β-cells (HOMA-β), Changes in the functions of islet β-cells in patients after five weeks of treatment (measured by the Homeostatic Model Assessment of β-cell function HOMA-β), Baseline and week5|Changes in the function of islet β-cells (insulin index ΔI30 / ΔG30), Changes in the functions of islet β-cells in patients after five weeks of treatment (measured by insulin index ΔI30 / ΔG30);, Baseline and week5|Changes in insulin sensitivity, Changes in insulin sensitivity in the two patient groups after five weeks of treatment (measured by the Homeostatic Model Assessment of Insulin Resistance - HOMA-IR)., Baseline and week5|Changes in β-cell function (HOMA-β), After 53 weeks, the following indices for responders who meet the HbA1c criteria will be compared between the two treatment groups: HOMA-β changes at week 53 from baseline, Baseline and week53|Weight changes between the two treatment groups, After 53 weeks, the following indices for responders who meet the HbA1c criteria will be compared between the two treatment groups: weight changes at week 53 from baseline, Baseline and week53|Weight changes between the two treatment groups, After 53 weeks, the following indices for responders who meet the HbA1c criteria will be compared between the two treatment groups: weight changes at week 53 from week 5, week5 and week53|The percentage of responders who meet the HbA1c criteria, The percentage of responders who meet the HbA1c criteria at week 53 will be compared between the Beinaglutide-treated group and the insulin aspart-treated group, Baseline and week53|The differences in the duration of target blood glucose levels that are met, The difference in the duration during which the criteria of blood glucose levels are met will be compared, Baseline and week53|The percentages of responders who meet the HbAc1 criteria, The percentages of responders who meet the HbAc1 criteria at week 17 from the end of treatments will be compared, week5 and week17|Weight changes between the two treatment groups, The percentages of responders who meet the weight changes at week 17 from the end of treatments will be compared, week5 and week17|Differences in HbA1c indices, Analyze the differences in HbA1c indices for responders who meet the HbA1c criteria and non-responders who failed the HbA1c criteria after 5-week treatment, respectively, Week5 and week29|Differences in weight, Analyze the differences in weight for responders who meet the HbA1c criteria and non-responders who failed the HbA1c criteria after 5-week treatment, respectively, Week5 and week29|Differences in HbA1c indices, Analyze the differences in HbA1c indices for responders who meet the HbA1c criteria and non-responders who failed the HbA1c criteria at week 53, respectively, Week5 and week53|Differences in weight, Analyze the differences in weight for responders who meet the HbA1c criteria and non-responders who failed the HbA1c criteria at week 53, respectively, Week5 and week53|Differences in insulin levels, Analyze the differences in insulin for responders who meet the HbA1c criteria and non-responders who failed the HbA1c criteria at week 53, respectively, Week5 and week53|Differences in C-peptide levels, Analyze the differences in C-peptide for responders who meet the HbA1c criteria and non-responders who failed the HbA1c criteria at week 53, respectively, Week5 and week53|The percentages of subjects with greater than 3% weight loss, The percentages of subjects with weight loss at week 53 from baseline greater than 3% will be compared between the two treatment groups, Baseline and week53
|
| Locations: |
First Hospital of Peking University, Beijing, China,Beijing, 100034, China|Ninth Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Fuzhou, China,Fuzhou, 350025, China|Southern Hospital of Southern Medical University, Guangzhou, China,Guangzhou, 510515, China|Heilongjiang provincial hospital, Harbin, China,Harbin, 150030, China|Henan People's Hospital, Zhengzhou, China,Zhengzhou, 450003, China|Tangshan Workers Hospital, Tangshan, Hebei,Tangshan, 063000, China|Affiliated Hospital of Qingdao University, Qingdao, Shandong，Qingdao, 266000, China|Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan，Sichuan, 646000, China|Zhejiang People's Hospital, Hangzhou, Zhejiang,Hangzhou, 310014, China
|
